Efficiency of Combined Therapy with Impaza and Type 5 Phosphodiesterase Inhibitors in Prophylactics of Posttraumatic Erectile Dysfunction

After the advent of four type 5 phosphodiesterase inhibitors (PDEI 5), viz. sildenafil, tadalafil, vardenafil, and udenafil, designed for the treatment of erectile dysfunction both physicians and patients found themselves faced with the problem of choosing an optimal therapeutic option. This paper contains comparative data on the efficacy and safety of different PDEI 5. The approaches to the rational choice of these preparations for the treatment of patients presenting with cardiovascular and endocrine diseases are discussed. Comparative controlled clinical studies failed to yield definitive information about advantages of one or another agent representing this group of pharmaceutical products. Nevertheless, the currently available data permit to draw the conclusion that the use of vardenafil and tadalafil ensures better compliance of patients with the prescribed therapy. Certain authors advocate the desirability of vardenafil application to the treatment of patients presenting with a background pathology. It is emphasized that all available PDEI 5 have a beneficial safety profile, with wardenafil being virtually free from adverse side effects.

Download Full-text

Type 5 Phosphodiesterase Inhibitors: Curing Erectile Dysfunction

European Urology ◽

10.1016/j.eururo.2006.02.063 ◽

2006 ◽

Vol 49 (6) ◽

pp. 942-945 ◽

Cited By ~ 9

Author(s):

Wayne J.G. Hellstrom ◽

Muammer Kendirci

Keyword(s):

Erectile Dysfunction ◽

Phosphodiesterase Inhibitors ◽

Type 5 Phosphodiesterase Inhibitors

Download Full-text

ERECTILE DYSFUNCTION AND ITS PHARMACOLOGY: AN OVERVIEW

Asian Journal of Pharmaceutical and Clinical Research ◽

10.22159/ajpcr.2017.v10i2.15183 ◽

2017 ◽

Vol 10 (2) ◽

pp. 17 ◽

Cited By ~ 1

Author(s):

Sunil Kumar Patnaik ◽

Haritha Polimati ◽

Rajeswara Rao Pragada

Keyword(s):

Diabetes Mellitus ◽

Risk Factors ◽

Erectile Dysfunction ◽

Cigarette Smoking ◽

Penile Erection ◽

Treatment Strategies ◽

Phosphodiesterase Inhibitors ◽

Current Treatment ◽

Complex Nature ◽

Factors Associated

It has been estimated that currently over 150 million men worldwide suffer from erectile dysfunction (ED) and by 2025, the figure will increase beyond 322 millions. ED is the inability to achieve, and/or maintain penile erection sufficient for satisfactory sexual intercourse, and was previously regarded as the part of aging. It is associated with certain diseases and life style habits with a cause-effect relationship, including diabetes mellitus, hypertension, dyslipidemia, and cigarette smoking. Internationally, most of the men with ED fail to pursue treatment due to the complex nature of sexuality, taboos, cultural restrictions, and acceptance of ED as a normal sequel of aging. In this review, we discussed the physiology, diagnosis, and risk factors associated with ED and current treatment strategies for ED.Keywords: Erectile dysfunction, Diabetes, Penile erection, Phosphodiesterase inhibitors.

Download Full-text

Low intensity Extra Corporeal Shock Wave Therapy in Patients with Erectile Dysfunction: Our experience in ACKU

Bangladesh Journal of Urology ◽

10.3329/bju.v23i2.50311 ◽

2020 ◽

Vol 23 (2) ◽

pp. 176-180

Author(s):

Md Fazal Naser ◽

Mahmood Hasan ◽

Md Waliul Islam ◽

Tajkera Sultana Chowdhury ◽

Md Shohrab Hossain

Keyword(s):

Erectile Dysfunction ◽

Erectile Function ◽

Treatment Protocol ◽

Phosphodiesterase Inhibitors ◽

Shockwave Therapy ◽

Low Intensity ◽

Weekly Session ◽

Linear Probe ◽

Study Population ◽

Energy Flux Density

Introduction: Oral 5-phosphodiesterase inhibitors (PDE5-I) is the main therapeutical options in erectile dysfunction (ED). It shows good results, but non-responders lack other effective options and its effect is also not long lasting. Since last few years, low-intensity extracorporeal shockwave therapy (Li-ESWT) in the corpora cavernosa showing promising results. This article presents our early experiences in Advanced Center of Kidney disease and Urology (ACKU) with the aim to evaluate clinical efficacy of Li-ESWT. Materials and methods: Thirty four patients with ED were prospectively included in the study during the period of January 2018 to Jun 2019.Treatment was performed using the PiezoWave2 (Richard Wolf, Germany) device with a linear probe. Treatment protocol included a weekly session for four weeks. Each session delivered 2000 shocks on the perineum plus 4000 shocks on dorsum penis with an energy flux density (EFD) of 0.160 mJ/mm2. Every patient has been re-evaluated 1.5 and 3 months after the last session. Pre- and post-procedure International Index Erectile Function – Erectile function domain (IIEF-EF) score, Erection Hardness Score (EHS) and Global Assessment Questionnaire-Question 1 (GAQ-Q1) answers were obtained. Results: Mean age of the study population was 39.4 (±12.9) years, 35.29% diabetic, 20.59% with hypertension and 55.85% smokers. Mean baseline IIEF-EF was 14.6, at 6 week post LiSWT was 16.4 (p >0.05) and at 3 months post LiSWT was 19.2 (p < 0.05). EHS was significantly improved at 3 month in comparison to baseline (p<0.05). 20.59% patients answered positively to GAQ-Q1 at 6 week and 61.76% at 3 months. IIEF-EF score change of >5 and increase of EHS >2 were observed in 62.88% and 70.59% study subjects respectively. Conclusions: Li-ESWT is a safe, harmless and repeatable treatment tool for ED with good outcomes reported. Bangladesh Journal of Urology, Vol. 23, No. 2, July 2020 p.176-180

Download Full-text